Atomoxetine–Fluoxetine Combination Safety
Fluoxetine is a potent CYP2D6 inhibitor, and co-administration with atomoxetine substantially increases atomoxetine plasma exposure. [1] [2] Because of this pharmacokinetic interaction, atomoxetine should be dose-adjusted and monitored for increased adverse effects when fluoxetine is used concurrently. [1] [2]
Pharmacokinetic Interaction Mechanism
Atomoxetine is metabolized primarily via CYP2D6 to 4-hydroxyatomoxetine. [1] Strong CYP2D6 inhibitors including fluoxetine increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in CYP2D6 poor metabolizers. [1]
Dose Adjustment Recommendation
When atomoxetine is coadministered with potent CYP2D6 inhibitors (including fluoxetine), a dosing adjustment may be necessary. [1] [2] In children and adolescents ≤70 kg receiving atomoxetine with strong CYP2D6 inhibitors (including fluoxetine), atomoxetine should be initiated at 0.5 mg/kg/day and increased to 1.2 mg/kg/day only if symptoms fail to improve after 4 weeks and the initial dose is well tolerated. [3]
Safety Monitoring Considerations
Increased atomoxetine exposure is expected with fluoxetine, which increases the likelihood of atomoxetine-related adverse effects. [1] [2] Monitoring should focus on atomoxetine adverse effects occurring at higher exposures, including cardiovascular effects (eg, elevated heart rate and blood pressure) and other dose-related tolerability issues described for atomoxetine. [1]
Serotonin Syndrome Risk
Atomoxetine has serotonergic pharmacologic activity, and serotonin syndrome has been reported with atomoxetine in combination with other serotonergic agents. [4] The presence of a direct, labeling-level serotonin-syndrome risk statement specifically for atomoxetine plus fluoxetine is not required for safe co-use, but concurrent serotonergic therapy should still prompt monitoring for serotonin-toxicity symptoms. [4]
Common Pitfalls to Avoid
Omission of CYP2D6-inhibitor dose adjustment is a key avoidable error because fluoxetine increases atomoxetine exposure to poor-metabolizer–like levels. [1] [2]
Practical Risk-Control Strategy
CYP2D6-inhibitor co-therapy with fluoxetine should be managed using labeled atomoxetine dosing adjustments and clinical monitoring for increased adverse effects. [1] [3]
Contraindications
No contraindication is listed in atomoxetine labeling for concurrent use with fluoxetine. [1]